Search

Your search keyword '"Eberhardt, Christiane S"' showing total 194 results

Search Constraints

Start Over You searched for: Author "Eberhardt, Christiane S" Remove constraint Author: "Eberhardt, Christiane S"
194 results on '"Eberhardt, Christiane S"'

Search Results

2. Contributors

3. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

4. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

5. A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project

6. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity

11. Immune escape of Omicron lineages BA.1, BA.2, BA.5.1, BQ.1, XBB.1.5, EG.5.1 and JN.1.1 after vaccination, infection and hybrid immunity

17. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study

19. Reply to Abu Raya et al

21. Antibody response in children with multisystem inflammatory syndrome related to COVID-19 (MIS-C) compared to children with uncomplicated COVID-19

22. T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

23. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

25. Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis

26. Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence

27. Contrasting behavior between the three human monocyte subsets in dengue pathophysiology

28. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab

31. Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants

32. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

33. Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients

35. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study

38. Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence.

39. SARS‐CoV‐2 infection as a trigger of humoral response against apolipoprotein A‐1

41. Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines

43. Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection

44. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.

46. Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association With Viral Load, Independent of Symptoms

47. SARS-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

50. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series

Catalog

Books, media, physical & digital resources